NCT05773859View on ClinicalTrials.gov

NEOadjuvant Dendritic Cell Vaccination for Ovarian Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 17, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Epithelial Ovarian CancerOvarian Carcinoma
Interventions
BIOLOGICAL

XP-DC vaccinations

Autologous cross-presenting dendritic cells loaded with autologous tumor lysate and KLH

Trial Locations (1)

6500 HB

RECRUITING

Radboud University Medical Center, Nijmegen

All Listed Sponsors
lead

Radboud University Medical Center

OTHER